Condition: Hepatitis B · Sponsor: Sclnow Biotechnology Co., Ltd.
1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat. 3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.
This description comes directly from the study's public registry record.
Lei Guo, doctor · 861064368977 · georgeguo@sclnow.com
Xuegong Fan, doctor · 86731-84327392 · xgfan@hotmail.com
Always discuss trial participation with your own doctor first.
| Xiangya Hospital Central South University | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03826433